China Shineway Pharmaceutical Group Limited (HKG:2877)
Hong Kong · Delayed Price · Currency is HKD 7.43
+0.09 (1.16%)
Oct 9, 2026, 4:08 PM HKT
HKG:2877 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,664 | 3,135 | 3,778 | 4,517 | 3,951 | 3,224 | |
Revenue Growth | -20.34% | -17.01% | -16.35% | 14.32% | 22.55% | 21.38% |
Cost of Revenue | 765.59 | 869.21 | 946.29 | 1,122 | 1,012 | 813.21 |
Gross Profit | 1,898 | 2,266 | 2,832 | 3,394 | 2,938 | 2,410 |
Selling, General & Admin | 1,090 | 1,445 | 1,889 | 2,308 | 2,098 | 1,756 |
Research & Development | 119.69 | 103.1 | 100.52 | 110.46 | 117.45 | 112.71 |
Operating Expenses | 1,247 | 1,584 | 1,996 | 2,424 | 2,225 | 1,876 |
Operating Income | 650.83 | 682.07 | 835.99 | 970.1 | 713.58 | 534.37 |
Interest Expense | -5.69 | -5.69 | -6.13 | -2.74 | -0.63 | -1.25 |
Interest & Investment Income | 288.01 | 393.31 | 189.35 | 105.51 | 99.1 | 104.14 |
Currency Exchange Gain (Loss) | -26.81 | 31.16 | -55.44 | 6.61 | -8.52 | -2.9 |
Other Non Operating Income (Expenses) | 141.74 | 163.58 | 177.94 | 163.17 | 113.37 | 102.23 |
EBT Excluding Unusual Items | 1,048 | 1,264 | 1,142 | 1,243 | 916.9 | 736.58 |
Gain (Loss) on Sale of Assets | 14.82 | 4.83 | 4.01 | -2.39 | 0.13 | -16.47 |
Pretax Income | 1,063 | 1,269 | 1,146 | 1,240 | 917.03 | 720.1 |
Income Tax Expense | 258.45 | 319.32 | 305.67 | 270.74 | 194.25 | 163.43 |
Earnings From Continuing Operations | 804.44 | 949.95 | 840.05 | 969.51 | 722.77 | 556.67 |
Net Income | 804.44 | 949.95 | 840.05 | 969.51 | 722.77 | 556.67 |
Net Income to Common | 804.44 | 949.95 | 840.05 | 969.51 | 722.77 | 556.67 |
Net Income Growth | -2.87% | 13.08% | -13.35% | 34.14% | 29.84% | 88.68% |
Shares Outstanding (Basic) | 755 | 755 | 755 | 755 | 755 | 755 |
Shares Outstanding (Diluted) | 755 | 755 | 755 | 755 | 755 | 755 |
Shares Change | - | - | - | - | 0.03% | -0.21% |
EPS (Basic) | 1.06 | 1.26 | 1.11 | 1.28 | 0.96 | 0.74 |
EPS (Diluted) | 1.06 | 1.26 | 1.11 | 1.28 | 0.96 | 0.74 |
EPS Growth | -2.30% | 13.29% | -13.51% | 34.14% | 29.79% | 89.08% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 704.48 | 974.13 | 823.02 | 788.31 | 980.21 | 609.52 |
Free Cash Flow Per Share | 0.93 | 1.29 | 1.09 | 1.04 | 1.30 | 0.81 |
Dividend Per Share | 1.230 | 0.470 | 0.540 | 0.420 | 0.320 | 0.390 |
Dividend Growth | 161.70% | -12.96% | 28.57% | 31.25% | -17.95% | 21.88% |
Gross Margin | 71.26% | 72.28% | 74.95% | 75.15% | 74.38% | 74.77% |
Operating Margin | 24.43% | 21.75% | 22.13% | 21.48% | 18.06% | 16.58% |
Profit Margin | 30.20% | 30.30% | 22.23% | 21.47% | 18.30% | 17.27% |
Free Cash Flow Margin | 26.45% | 31.07% | 21.78% | 17.45% | 24.81% | 18.91% |
EBITDA | 705.05 | 739.53 | 891.44 | 1,019 | 888.23 | 705.11 |
EBITDA Margin | 26.47% | 23.59% | 23.59% | 22.56% | 22.48% | 21.87% |
D&A For EBITDA | 54.22 | 57.46 | 55.45 | 49.02 | 174.65 | 170.75 |
EBIT | 650.83 | 682.07 | 835.99 | 970.1 | 713.58 | 534.37 |
EBIT Margin | 24.43% | 21.75% | 22.13% | 21.48% | 18.06% | 16.58% |
Effective Tax Rate | 24.32% | 25.16% | 26.68% | 21.83% | 21.18% | 22.70% |